In this interview, Curtis Triplitt, PharmD, associate professor and assistant dean of research, Texas Tech University Health Sciences Center, Permian Basin, explains why diabetes should be treated with a patient-centered approach.
In this interview, Curtis Triplitt, PharmD, associate professor and assistant dean of research, Texas Tech University Health Sciences Center, Permian Basin, explains why diabetes should be treated with a patient-centered approach. This means that therapies should be based on an individual, not a population. Patient-centered approaches require payer and provider to examine a patient’s specific characteristics and needs such as race, gender, comorbidities, and motivation. “You take those different characteristics of a patient, apply them to a particular drug, and see if they fit,” said Dr Triplitt. He compared prescribing a DPP-4 inhibitor, a well- tolerated once-a day-oral medication that fits well in a large population, with pramlintide, used in combination with insulin and in a smaller population.
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity
July 1st 2025Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen